SELLAS Life Sciences Group (SLS) to Release Quarterly Earnings on Thursday

SELLAS Life Sciences Group (NASDAQ:SLS) will likely be issuing its Q4 2025 results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of ($0.0633) per share for the quarter. Investors are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 25, 2026 at 4:00 PM ET.

SELLAS Life Sciences Group Price Performance

NASDAQ:SLS opened at $5.36 on Tuesday. The company has a 50 day moving average price of $4.36 and a 200-day moving average price of $2.82. SELLAS Life Sciences Group has a 1-year low of $0.95 and a 1-year high of $6.14. The firm has a market cap of $763.48 million, a price-to-earnings ratio of -19.14 and a beta of 2.18.

Institutional Investors Weigh In On SELLAS Life Sciences Group

Hedge funds have recently modified their holdings of the business. Invesco Ltd. lifted its stake in shares of SELLAS Life Sciences Group by 6.2% in the fourth quarter. Invesco Ltd. now owns 53,293 shares of the company’s stock worth $201,000 after buying an additional 3,114 shares in the last quarter. The Manufacturers Life Insurance Company grew its stake in SELLAS Life Sciences Group by 13.6% during the 4th quarter. The Manufacturers Life Insurance Company now owns 38,018 shares of the company’s stock valued at $143,000 after acquiring an additional 4,564 shares in the last quarter. Equitable Holdings Inc. grew its stake in SELLAS Life Sciences Group by 18.5% during the 4th quarter. Equitable Holdings Inc. now owns 32,060 shares of the company’s stock valued at $121,000 after acquiring an additional 5,000 shares in the last quarter. Bank of America Corp DE raised its holdings in SELLAS Life Sciences Group by 21.9% in the 3rd quarter. Bank of America Corp DE now owns 42,150 shares of the company’s stock valued at $68,000 after acquiring an additional 7,571 shares during the last quarter. Finally, BNP Paribas Financial Markets raised its holdings in SELLAS Life Sciences Group by 89.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,724 shares of the company’s stock valued at $32,000 after acquiring an additional 9,299 shares during the last quarter. 17.38% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a research report on Thursday, January 22nd. Maxim Group upped their price objective on shares of SELLAS Life Sciences Group from $7.00 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, March 12th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, SELLAS Life Sciences Group currently has an average rating of “Hold” and a consensus target price of $10.00.

About SELLAS Life Sciences Group

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.